The purpose of this study was to investigate the relationship between medications for opioid use disorder (MOUD) attitudes and MOUD use in recovery residences (RRs). It was hypothesized that RR leaders with positive attitudes about MOUD will report more types of MOUD accepted in their RR, and greater MOUD use among their residents, than leaders with negative attitudes.
Method:
Data for this study were collected through an online survey of RR owners, operators, and managers in 20 states in the United States (n = 128). MOUD attitudes were assessed with 2 scales developed for this study. Both ideological (α = .90) and logistical (α = .77) attitudes scales showed good internal reliability. Poisson and ordinary least squares (OLS) regression were used to examine the association between MOUD attitudes, and the number of medications accepted and used in RRs, holding constant participant’s time in role, RR level, proportion of non-white residents, bed number, whether the RR accepts females, and state.
Results:
Most participants reported that their RR accepted MOUD (92%) and a little under half preferred certain types of MOUD (46%). The Poisson and OLS regression revealed that more positive ideology toward MOUD was significantly associated with increases in both the total number of medications accepted in the RR and the extent of MOUD use among residents.
Implications:
Attitudes of RR leadership relate to MOUD practices among RR residents. Changing leaders’ attitudes could influence the integration of MOUD use in RRs.
Centers for Disease Control and Prevention. U.S. overdose deaths decrease in 2023, first time since 2018. National Center for Health Statistics (NCHS) Pressroom. May 15, 2024. https://www.cdc.gov/nchs/pressroom/releases/20240515.html
2.
AnderssonHWWenaasMNordfjærnT.Relapse after inpatient substance use treatment: a prospective cohort study among users of illicit substances. Addict Behav. 2019;90:222-228. doi:10.1016/j.addbeh.2018.11.008
3.
DavidARSianCRGebelCM, et al. Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): a qualitative study. J Subst Abuse Treat. 2022;142:108870. doi:10.1016/j.jsat.2022.108870
4.
BausADCarterMBoydJ, et al. A better life: factors that help and hinder entry and retention in mat from the perspective of people in recovery. J Appalach Health. 2023;5(1):72-94. doi:10.13023/jah.0501.06
5.
BremerWPlaisanceKWalkerD, et al. Barriers to opioid use disorder treatment: a comparison of self-reported information from social media with barriers found in literature. Front Public Health. 2023;11:1141093. doi:10.3389/fpubh.2023.1141093
6.
Dickson-GomezJSpectorAWeeksMGalletlyCMcDonaldMGreen MontaqueHD.“You’re not supposed to be on it forever”: medications to Treat Opioid Use Disorder (MOUD) related stigma among drug treatment providers and people who use opioids. Subst Abuse. 2022;16:11782218221103859. doi:10.1177/11782218221103859
7.
MaJBaoYPWangRJ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Molecular Psychiatry. 2019;24(12):1868-1883. doi:10.1038/s41380-018-0094-5
8.
TimkoCSchultzNRCucciareMAVittorioLGarrison-DiehnC.Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22-35. doi:10.1080/10550887.2016.1100960
9.
WakemanSELarochelleMRAmeliO, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. doi:10.1001/jamanetworkopen.2019.20622
10.
Substance Abuse and Mental Health Services Administration (SAMHSA). Medication-Assisted Treatment (MAT). MAT. Published June 28, 2022. Accessed June 30, 2022. https://www.samhsa.gov/medication-assisted-treatment
DeverJAHertzMFDunlapLJ, et al. The medications for opioid use disorder study: methods and initial outcomes from an 18-month study of patients in treatment for opioid use disorder. Public Health Rep. 139;484-493. doi:10.1177/00333549231222479
13.
Andraka-ChristouBGabrielMMadeiraJSilvermanRD.Court personnel attitudes towards medication-assisted treatment: a state-wide survey. J Subst Abuse Treat. 2019;104:72-82. doi:10.1016/j.jsat.2019.06.011
14.
CalcaterraSLBachPChadiA, et al. Methadone matters: what the united states can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019;34(6):1039-1042. doi:10.1007/s11606-018-4801-3
15.
DavenportESArnettSJNicholsMAMillerML.Indiana community pharmacist preceptors’ knowledge and perceptions of medication-assisted treatment. J Am Pharma Assoc. 2020;60(3 Suppl.):S20.e4-S28.e4. doi:10.1016/j.japh.2020.01.001
16.
Garcia-PortillaMPBobes-BascaranMTBascaranMTSaizPABobesJ.Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?Br J Clin Pharmacol. 2014;77(2):272-284. doi:10.1111/bcp.12031
17.
CarlAPasmanEBromanMJListerJJAgiusEReskoSM.Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug Alcohol Depend Rep. 2023;6:100138. doi:10.1016/j.dadr.2023.100138
18.
DobkinPLCivitaMDParaherakisAGillK.The role of functional social support in treatment retention and outcomes among outpatient adult substance abusers. Addiction. 2002;97(3):347-356. doi:10.1046/j.1360-0443.2002.00083.x
19.
WooJBhaleraoABaworM, et al. “Don’t judge a book by its cover”: a qualitative study of methadone patients’ experiences of stigma. Subst Abuse. 2017;11:1178221816685087. doi:10.1177/1178221816685087
20.
JonesCMHanBBaldwinGTEinsteinEBComptonWM.Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Network Open. 2023;6(8):e2327488. doi:10.1001/jamanetworkopen.2023.27488
RobertsAWSalonerBDusetzinaSB.Buprenorphine use and spending for opioid use disorder treatment: trends from 2003 to 2015. Psychiatr Serv. 2018;69(7):832-835. doi:10.1176/appi.ps.201700315
23.
MancherMLeshnerAI, National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. National Academies Press; 2019.
24.
KrawczykNRiveraBDJentVKeyesKMJonesCMCerdáM.Has the treatment gap for opioid use disorder narrowed in the U.S.? A yearly assessment from 2010 to 2019. Int J Drug Policy. 2022;110:103786. doi:10.1016/j.drugpo.2022.103786
25.
SolomonKTBandaraSReynoldsIS, et al. Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: a state-level trends analysis. J Subst Abuse Treat. 2022;132:108424. doi:10.1016/j.jsat.2021.108424
26.
MericleAAPattersonDHowellJSubbaramanMSFaxioAKarriker-JaffeKJ.Identifying the availability of recovery housing in the U.S.: the NSTARR project. Drug Alcohol Depend. 2022;230:109188. doi:10.1016/j.drugalcdep.2021.109188
27.
PolcinDLKorchaRBondJGallowayGLappW.Recovery from addiction in two types of sober living houses: 12-month outcomes. Addict Res Theory. 2010;18(4):442-455. doi:10.3109/16066350903398460
28.
JasonLAMajerJMBobakTJO’BrienJ.Medication assisted therapy and recovery homes. J Prevent Intervent Commun. 2022;50(2):178-190. doi:10.1080/10852352.2021.1934940
29.
MajerJMBobakTJJasonLA.Homophily effects among oxford house residents utilizing medication assisted treatment. Alcohol Treat Quarter. 2021;39(1):16-29. doi:10.1080/07347324.2020.1738296
30.
MajerJMJasonLAHickeyPJoshuaNJeongHBobakTJ.Social support among oxford house residents utilizing medication-assisted treatments. Alcohol Treat Quarter. 2020;38(2):199-214. doi:10.1080/07347324.2019.1678445
31.
BorkmanTJKaskutasLARoomJBryanKBarrowsD.An historical and developmental analysis of social model programs. J Subst Abuse Treat. 1998;15(1):7-17. doi:10.1016/s0740-5472(97)00244-4
32.
FuttermanRLorenteMSilvermanS.Integrating harm reduction and abstinence-based substance abuse treatment in the public sector. Subst Abuse. 2004;25(1):3-7. doi:10.1300/J465v25n01_02
WoodCADuelloAMilesJ, et al. Acceptance of medications for opioid use disorder in recovery housing programs in Missouri. J Subst Abuse Treat. 2022;138:108747. doi:10.1016/j.jsat.2022.108747
MajerJMBeasleyCSteckerE, et al. Oxford house residents’ attitudes toward medication assisted treatment use in fellow residents. Community Ment Health J. 2018;54(5):571-577. doi:10.1007/s10597-017-0218-4
38.
GallardoKRWilkersonJMStewartHLNZoschkeINFredriksen IsaacsCMcCurdySA.“Being here is saving my life”: resident experiences of living in recovery residences for people taking medication for an opioid use disorder. J Subst Use Addict Treat. 2024;158:209242. doi:10.1016/j.josat.2023.209242
39.
Soto-NevarezAAboMHudsonMBobakTJasonLA.Lived experiences of Oxford House residents prescribed medication-assisted treatment. J Commun Psychol. 2023;51(7):2828-2844. doi:10.1002/jcop.23038
40.
KeglerMCLiangSWeinerBJ, et al. Measuring constructs of the consolidated framework for implementation research in the context of increasing colorectal cancer screening in federally qualified health center. Health Serv Res. 2018;53(6):4178-4203. doi:10.1111/1475-6773.13035
41.
McElrathK.Medication-assisted treatment for opioid addiction in the United States: critique and commentary. Subst Use Misuse. 2018;53(2):334-343.
MilesJHowellJSheridanDBrauchtGMericleA.Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic. Am J Drug Alcohol Abuse. 2020;46(3):266-272. doi:10.1080/00952990.2020.1719410
44.
ShresthaN.Factor analysis as a tool for survey analysis. Am J Appl Math Stat (Online). 2021;9(1):4-11. doi:10.12691/ajams-9-1-2
45.
DamschroderLJAronDCKeithREKirshSRAlexanderJALoweryJC.Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4(1):50. doi:10.1186/1748-5908-4-50
46.
LagisettyPARossRBohnertAClayMMaustDT.Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry (Chicago, Ill). 2019;76(9):979-981. doi:10.1001/jamapsychiatry.2019.0876
47.
HansenHSiegelCWanderlingJDiRoccoD.Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Depend. 2016;164:14-21. doi:10.1016/j.drugalcdep.2016.03.028
48.
AaronsGHurlburtMHorwitzSM.Advancing a conceptual model of evidence-based practice implementation in public service sectors. Admin Policy Ment Health. 2022;38(1):4-23. doi:10.1007/s10488-010-0327-7
49.
GrellaCE.From generic to gender-responsive treatment: changes in social policies, treatment services, and outcomes of women in substance abuse treatment. J Psych Drug. 2008;40(Suppl. 5):327-343. doi:10.1080/02791072.2008.10400661
50.
BlanchardJWeissA j.BarrettWLMcDermottKWHeslinnKC. State variation in opioid treatment policies and opioid-related hospital readmissions. BMC Health Serv Res. 18(1):971. doi:10.1186/s12913-018-3703-8
ShoverCL.Availability of extended-release buprenorphine to treat opioid use disorders among Medicaid-covered patients. PS. 2021;72(2):225-226. doi:10.1176/appi.ps.202000165
53.
WeissFCiccocioppoRParsonsLH, et al. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci. 2001;937:1-26. doi:10.1111/j.1749-6632.2001.tb03556.x
PasmanELeeGSingerSBursonNAgiusEReskoSM.Attitudes toward medications for opioid use disorder among peer recovery specialists. Am J Drug Alcohol Abuse. 2024;50(3):391-400. doi:10.1080/00952990.2024.2332597
57.
SuzukiJLoguidiceFMartinB.Attitudes regarding medications for opioid use disorder among peer recovery coaches. J Addict Med. 2023;17(1):101-103. doi:10.1097/ADM.0000000000001025
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
